HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1

被引：0

作者：

Braso-Maristany, F. ^{[1
]}

Griguolo, G. ^{[2
]}

Chic, N. ^{[3
]}

Pare Brunet, L. ^{[3
]}

Galvan, P. ^{[4
]}

Dieci, M. V. ^{[5
]}

Miglietta, F. ^{[6
]}

Giarratano, T. ^{[7
]}

Martinez-Saez, O. ^{[8
]}

Marin, M. ^{[8
]}

Vidal Losada, M. J. ^{[9
]}

Adamo, B. ^{[10
]}

Munoz, M. ^{[11
]}

Vivancos, A. ^{[12
]}

Villagrasa Gonzalez, P. ^{[13
]}

Parker, J. ^{[13
]}

Perou, C. M. ^{[14
]}

Conte, P. F. ^{[15
]}

Prat, A. ^{[16
]}

Guarneri, V. ^{[17
]}

机构：

[1] IDIBAPS Inst Invest Biomed August Pi & Sunyer, Dept Oncol, Barcelona, Spain

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[3] Reveal Genom SL, Dept Sci, Barcelona, Spain

[4] IDIBAPS August Pi & Sunyer Biomed Res Inst, Dept Med Oncol, Barcelona, Spain

[5] Univ Padua, DiSCOG, Padua, Italy

[6] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol, Padua, Italy

[7] IOV Ist Oncologico Veneto IRCCS, Dept Oncol, Padua, Italy

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Hosp Clin Barcelona, Breast Canc, Barcelona, Spain

[10] Hosp Clin Prov Barcelona, Breast Canc Dept, Barcelona, Spain

[11] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[12] Vall Hebron Univ sity Hosp, Genom Dept, Barcelona, Spain

[13] UNC, Dept Oncol, Lineberger Canc Ctr, Chapel Hill, NC USA

[14] UNC, Dept Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[15] IOV Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol Dept, Padua, Italy

[16] Hosp Clin Prov Barcelona, Dept Med Oncol, Barcelona, Spain

[17] Univ Padua, Oncol & Gastroenterol Dept, Dept Surg, Padua, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.276

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

237P

引用

页码：S646 / S646

页数：1

共 50 条

[41] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
Satzger, Ulla
ONKOLOGIE, 2013, 36 (09): : 525 - 525
[42] T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
Fabi, Alessandra
Alesini, Daniele
Valle, Enrichetta
Moscetti, Luca
Caputo, Roberta
Caruso, Michele
Carbognin, Luisa
Ciccarese, Mariangela
La Verde, Nicla
Arpino, Grazia
Cannita, Katia
Paris, Ida
Santini, Daniele
Montemurro, Filippo
Russillo, Michelangelo
Ferretti, Gianluigi
Filippelli, Gianfranco
Rossello, Rosalba
Fabbri, Agnese
Zambelli, Alberto
Leonardi, Vita
D'Ottavi, Anna Maria
Nistico, Cecilia
Stani, Simonetta
Giampaglia, Marianna
Scandurra, Giusy
Catania, Giovanna
Malaguti, Paola
Giannarelli, Diana
Cognetti, Francesco
BREAST, 2018, 41 : 137 - 143
[43] HER2-positive advanced breast cancer
Robert, Nicholas J.
Favret, Anne M.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
[44] HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression
Di Cosimo, Serena
Serpico, Danila
Porcu, Luca
Tessari, Anna
Molino, Leonardo
Torri, Valter
de Braud, Filippo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
Martinez, Maria Teresa
Perez-Fidalgo, Jose Alejandro
Martin-Martorell, Paloma
Cejalvo, Juan Miguel
Pons, Vanesa
Bermejo, Begona
Martin, Miguel
Albanell, Joan
Lluch, Ana
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 96 - 106
[46] Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Burris, Howard A., III
Tibbitts, Jay
Holden, Scott N.
Sliwkowski, Mark X.
Phillips, Gail D. Lewis
CLINICAL BREAST CANCER, 2011, 11 (05) : 275 - 282
[47] Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Prat, Aleix
Guarneri, Valentina
Pascual, Tomas
Braso-Maristany, Fara
Sanfeliu, Esther
Pare, Laia
Schettini, Francesco
Martinez, Debora
Jares, Pedro
Griguolo, Gaia
Dieci, Maria Vittoria
Cortes, Javier
Llombart-Cussac, Antonio
Conte, Benedetta
Marin-Aguilera, Mercedes
Chic, Nuria
Puig-Butille, Joan Anton
Martinez, Antonio
Galvan, Patricia
Tsai, Yi-Hsuan
Gonzalez-Farre, Blanca
Mira, Aurea
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Conte, Pierfranco
Perou, Charles M.
EBIOMEDICINE, 2022, 75
[48] Outcome of HER2-Positive (HER2+) Metastatic Breast Cancer Patients (MBC) Treated with Trastuzumab (T): An Institutional Based Review
Guilhaume, M-N
Dieras, V
Fall, M.
Pierga, J-Y
Beuzeboc, P.
Cottu, P. H.
Simondi, C.
Courbard, M.
Mignot, L.
Livartowski, A.
CANCER RESEARCH, 2009, 69 (24) : 801S - 801S
[49] Impact on Survival of the Level of HER2/neu Gene Amplification in Patients with HER2-Positive (HER2+) Advanced Breast Cancer (AdvBrCa) Treated with Trastuzumab (H)
Gullo, G.
Bettio, D.
Zuradelli, M.
Masci, G.
Giordano, L.
Bareggi, C.
Salvini, P.
Runza, L.
Santoro, A.
CANCER RESEARCH, 2011, 71
[50] Enhanced antitumor efficacy of T-DM1 in combination with pertuzumab in HER2-positive breast cancer models
Sun, Yuliang
Dey, Nandini
Carlson, Jennifer
Brammer, Melissa
De, Pradip
Leyland-Jones, Brian
CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →